EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSPSNG00000015236
Gene Symbol: CACNG7
3 Cross references
253 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSPSNG00000015148
Gene Symbol: CACNG8
1 Cross references
238 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSPSNG00000003893
Gene Symbol: CACNA1A
3 Cross references
283 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSPSNG00000004873
Gene Symbol: CACNA1B
1 Cross references
287 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 C

Ensembl ID : ENSPSNG00000016230
Gene Symbol: CACNA1C
1 Cross references
211 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSPSNG00000022189
Gene Symbol: CACNA1D
3 Cross references
281 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSPSNG00000002084
Gene Symbol: CACNA1E
3 Cross references
294 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSPSNG00000022325
Gene Symbol: CACNA1F
3 Cross references
178 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSPSNG00000022489
Gene Symbol: CACNA1G
1 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSPSNG00000005454
Gene Symbol: CACNA1H
3 Cross references
201 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSPSNG00000008922
Gene Symbol: CACNA1I
1 Cross references
264 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSPSNG00000000547
Gene Symbol: CACNA1S
3 Cross references
259 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).